Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Biotechnology

Healthcare
$6.77 +1.96%

+$0.19 today

Market cap
$68.98M
Beta
0.11
P/E (TTM)
-14.7
EPS (TTM)
-$0.67
52W Low $3.92High $19.15

Volume 0.02M

Average 1.40M

ATRA Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Atara Biotherapeutics, Inc.NASDAQ: ATRA

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin narrows to -652.9%

Operating margin was -652.9% in Q1 FY2026, down 692.4 pp from a year earlier. On a trailing-twelve-month basis it was -27.3%, down 20.6 pp year over year. Over 3 fiscal years it widened by 470.9 pp.

Context

  • Operating margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 1 analysts of -226.4% for the fiscal year ending Dec 2026, down from 29.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-652.9%-492.2 pp QoQ
Last fiscal yearDec 2025
29.7%+94.4 pp YoY
LTMMar 2026
-27.3%-20.6 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-692.4 pp-861.2 pp-168.8 pp
1 year+94.4 pp-256.1 pp-350.5 pp
3 years+470.9 pp+6.0 pp-464.9 pp
5 years+23.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
29.7%
Year-over-year change
+94.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How ATRA compares with its peers on the latest reported figures

  • ATRA's LTM Mar 2026 operating margin of -27.3% is the 2nd highest of the 10 companies compared; the peer median is -670.2%.
  • Its year-over-year change of -20.6 pp is the 6th highest of 9, against a peer median of +5.1 pp.
  • Over three fiscal years its change of +470.9 pp compares with a peer median of +87.9 pp.
ATRA Competitors Peer median
Operating Margin for ATRA and competitors
Company Period LTM level YoY 3-year change
CSBRChampions Oncology, Inc.LTM Jan 2026-3.8% -14.6 pp+7.3 pp
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026-27.3% -20.6 pp+470.9 pp
MGNXMacroGenics, Inc.LTM Mar 2026-40.5% +24.7 pp+32.2 pp
STROSutro Biopharma, Inc.LTM Mar 2026-115.5% +261.4 pp+87.9 pp
COYACoya Therapeutics, Inc.LTM Mar 2026-277.0% +250.6 pp—
OVIDOvid Therapeutics Inc.LTM Mar 2026-670.2% +9733.9 pp+3111.2 pp
ORMPOramed Pharmaceuticals Inc.FY2025-754.4% —+747.6 pp
STTKShattuck Labs, Inc.LTM Mar 2026-5266.4% -3640.0 pp+10697.2 pp
CLNNClene Inc.LTM Mar 2026-15535.1% -7553.1 pp-1307.0 pp
IFRXInflaRx N.V.LTM Mar 2026-144445.0% -103193.3 pp—
CNTXContext Therapeutics Inc.FY2025— ——
Peer median (excluding ATRA) -670.2%+5.1 pp+87.9 pp

Competitors are the stored peer set for ATRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.34M63.57M8.57M128.94M120.77M
Cost of Revenue282M269.99M8.89M21.01M21.21M
Gross Profit(261.66M)(206.42M)(313K)107.93M99.56M
Gross Margin-1286.4%-324.7%-3.7%83.7%82.4%
Research & Development282M272.53M224.79M151.48M37.45M
Selling, General & Admin78.8M68.13M50.91M39.89M26.25M
Operating Expenses78.8M74.1M275.69M191.37M63.7M
Depreciation & Amortization9.35M5.65M4.83M5.05M2.12M
EBITDA(330.75M)(222.26M)(266M)(75.75M)38.63M
EBITDA Margin-1626.1%-349.6%-3102.7%-58.7%32.0%
Operating Income(340.46M)(280.51M)(276.01M)(83.44M)35.86M
Operating Margin-1673.9%-441.2%-3219.5%-64.7%29.7%
Interest Income367K3.06M5.43M2.11M683K
Interest Expense0373K5.29M4.62M3.79M
Other Income / Expenses367K52.22M(105K)(1.98M)(3.14M)
Income Before Tax(340.1M)(228.29M)(276.11M)(85.42M)32.72M
Pre-Tax Margin-1672.1%-359.1%-3220.7%-66.2%27.1%
Income Tax Expense46K12K15K(12K)31K
Net Income(340.14M)(228.3M)(276.13M)(85.4M)32.69M
Net Margin-1672.3%-359.1%-3220.9%-66.2%27.1%
EPS (Basic)(90.78)(55.96)(65.18)(11.41)2.61
EPS (Diluted)(90.78)(55.96)(65.18)(11.41)2.57
Weighted Avg Shares3.75M4.08M4.24M7.49M12.54M
Weighted Avg Shares (Diluted)3.75M4.08M4.24M7.49M12.72M

Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.